Pharma voices concerns over proposed EU guide on SUSAR reporting
This article was originally published in SRA
Executive Summary
The European Commission's draft guideline on reporting serious adverse events from clinical trials is more difficult to read and less useful to sponsors than the existing guidance documents on the topic, says the European federation of pharmaceutical industry associations, EFPIA1.